Buy Dutasteride (Avodart) online

Buy Avodart, Dutas (Dutasteride) 5-alpha-reductase inhibitor
Cheap qualitative Dutasteride 0.5 mg capsules or tablets online



HOW AND WHERE TO BUY DUTASTERIDE (AVODART) 0.5 MG CAPSULES OR TABLETS ONLINE:

AVODART: PRESCRIBING INFORMATION

DESCRIPTION

Avodart (Dutasteride) is a synthetic 4-azasteroid compound that is a selective inhibitor of both the type 1 and type 2 isoforms of steroid 5-alpha-reductase, an intracellular enzyme that converts testosterone to DHT.

Dutasteride is chemically designated as (5,17)-N-{2,5 bis(trifluoromethyl)phenyl}-3-oxo-4-azaandrost-1-ene-17-carboxamide. The empirical formula of dutasteride is C27H30F6N2O2, representing a molecular weight of 528.5.

Dutasteride is a white to pale yellow powder with a melting point of 242 to 250C. It is 337 soluble in ethanol (44 mg / mL), methanol (64 mg / mL), and polyethylene glycol 400 (3 mg / mL), but it is insoluble in water. Each Avodart soft gelatin capsule, administered orally, contains 0.5 mg of dutasteride dissolved in a mixture of mono-di-glycerides of caprylic / capric acid and butylated hydroxytoluene. The inactive excipients in the capsule shell are ferric oxide (yellow), gelatin (from certified BSE-free bovine sources), glycerin, and titanium dioxide. The soft gelatin capsules are printed with edible red ink.


INDICATIONS AND USAGE

Monotherapy

Avodart (Dutasteride) soft gelatin capsules are indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to:
  • improve symptoms,
  • reduce the risk of acute urinary retention (AUR), and
  • reduce the risk of the need for BPH-related surgery.

    Combination with alpha adrenergic antagonist

    Avodart in combination with the alpha adrenergic antagonist, tamsulosin, is indicated for the treatment of symptomatic BPH in men with an enlarged prostate.

    Limitations of use

    Avodart is not approved for the prevention of prostate cancer.


    DOSAGE AND ADMINISTRATION

    Avodart capsules should be swallowed whole and not chewed or opened, as contact with the capsule contents may result in irritation of the oropharyngeal mucosa. This medication may be administered with or without food.

    Monotherapy

    The recommended dose of Avodart is 1 capsule (0.5 mg) taken once daily.

    Combination with alpha adrenergic antagonist

    The recommended dose of Dutasteride is 1 capsule (0.5 mg) taken once daily and 22 tamsulosin 0.4 mg taken once daily.


    DOSAGE FORMS AND STRENGTHS

    0.5-mg, opaque, dull yellow, gelatin capsules imprinted with GX CE2 in red ink on one side.


    CONTRAINDICATIONS

    Avodart (Dutasteride) is contraindicated for use in:
  • Pregnancy. In animal reproduction and developmental toxicity studies, dutasteride inhibited development of male fetus external genitalia. Therefore, Avodart may cause fetal harm when administered to a pregnant woman. If this drug is used during pregnancy or if the patient becomes pregnant while taking Avodart, the patient should be apprised of the potential hazard to the fetus.
  • Women of childbearing potential.
  • Pediatric patients
  • Patients with previously demonstrated, clinically significant hypersensitivity (e.g., serious skin reactions, angioedema) to Avodart or other 5 alpha-reductase inhibitors.


    WARNINGS AND PRECAUTIONS

  • Avodart warnings and precautions


    ADVERSE REACTIONS

  • Avodart adverse reactions


    DRUG INTERACTIONS

    Cytochrome P450 3A inhibitors

    Dutasteride is extensively metabolized in humans by the CYP3A4 and CYP3A5 206 isoenzymes. The effect of potent CYP3A4 inhibitors on dutasteride has not been studied. Because of the potential for drug-drug interactions, use caution when prescribing Avodart to patients taking potent, chronic CYP3A4 enzyme inhibitors (e.g., ritonavir).

    Alpha-adrenergic antagonists

    The administration of Avodart (Dutasteride) in combination with tamsulosin or terazosin has no effect on the steady-state pharmacokinetics of either alpha-adrenergic antagonist. The effect of administration of tamsulosin or terazosin on dutasteride pharmacokinetic parameters has not been evaluated.

    Calcium channel antagonists

    Coadministration of verapamil or diltiazem decreases dutasteride clearance and leads to increased exposure to dutasteride. The change in this medication exposure is not considered to be clinically significant. No dose adjustment is recommended.

    Cholestyramine

    Administration of a single 5-mg dose of Avodart followed 1 hour later by 12 g of cholestyramine does not affect the relative bioavailability of dutasteride.

    Digoxin

    Avodart (Dutasteride) does not alter the steady-state pharmacokinetics of digoxin when administered concomitantly at a dose of 0.5 mg per day for 3 weeks.

    Warfarin

    Concomitant administration of Avodart 0.5 mg per day for 3 weeks with warfarin does 229 not alter the steady-state pharmacokinetics of the S- or R-warfarin isomers or alter the effect of warfarin on prothrombin time.


    USE IN SPECIFIC POPULATIONS

  • Avodart use in specific populations


    OVERDOSAGE

    In volunteer studies, single doses of Dutasteride (Avodart) up to 40 mg (80 times the therapeutic 320 dose) for 7 days have been administered without significant safety concerns. In a clinical study, daily doses of 5 mg (10 times the therapeutic dose) were administered to 60 subjects for 6 months with no additional adverse effects to those seen at therapeutic doses of 0.5 mg.

    There is no specific antidote for dutasteride. Therefore, in cases of suspected overdosage, symptomatic and supportive treatment should be given as appropriate, taking the long half-life of this medicine into consideration.


    CLINICAL PHARMACOLOGY

    Mechanism of action

    Dutasteride (Avodart) inhibits the conversion of testosterone to dihydrotestosterone (DHT). DHT is the androgen primarily responsible for the initial development and subsequent enlargement of the prostate gland. Testosterone is converted to DHT by the enzyme 5 alpha-reductase, which exists as 2 isoforms, type 1 and type 2. The type 2 isoenzyme is primarily active in the reproductive tissues, while the type 1 isoenzyme is also responsible for testosterone conversion in the skin and liver.

    This medication is a competitive and specific inhibitor of both type 1 and type 2 5-alpha-reductase isoenzymes, with which it forms a stable enzyme complex. Dissociation from this complex has been evaluated under in vitro and in vivo conditions and is extremely slow. Dutasteride does not bind to the human androgen receptor.

    Pharmacodynamics

  • Avodart pharmacodynamics

    Pharmacokinetics

  • Avodart pharmacokinetics


    NONCLINICAL TOXICOLOGY

  • Avodart nonclinical toxicology


    CLINICAL STUDIES

  • Avodart clinical studies


    HOW SUPPLIED

    Avodart soft gelatin capsules 0.5 mg are oblong, opaque, dull yellow, gelatin capsules imprinted with GX CE2 with red edible ink on one side packaged in bottles of 30 (NDC 0173-0712-15) and 90 (NDC 0173-0712-04) with child-resistant closures.


    STORAGE AND HANDLING

    Store at 25C (77F); excursions permitted to 15-30C (59-86F) [see USP Controlled Room Temperature].

    Avodart is absorbed through the skin. Dutasteride capsules should not be handled by women who are pregnant or who could become pregnant because of the potential for absorption of dutasteride and the subsequent potential risk to a developing male fetus.

    Manufactured and distributed by GlaxoSmithKline pharmaceutical company and its divisions.

    Recent posts:

  • Buy Avodart (Dutasteride) Online

    Copyright © Buy Dutasteride Online